Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation.

Eckman MH, Rosand J, Greenberg SM, Gage BF.

Ann Intern Med. 2009 Jan 20;150(2):73-83.

PMID:
19153410
2.

Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation.

Patrick AR, Avorn J, Choudhry NK.

Circ Cardiovasc Qual Outcomes. 2009 Sep;2(5):429-36. doi: 10.1161/CIRCOUTCOMES.108.808592. Epub 2009 Jul 21.

3.

Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy.

You JH, Tsui KK, Wong RS, Cheng G.

Clin Pharmacol Ther. 2009 Nov;86(5):540-7. doi: 10.1038/clpt.2009.104. Epub 2009 Jul 1.

PMID:
19571807
4.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.

Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP.

Ann Intern Med. 2011 Jan 4;154(1):1-11. doi: 10.7326/0003-4819-154-1-201101040-00289. Epub 2010 Nov 1.

PMID:
21041570
5.

Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation.

Cho HJ, On YK, Bang OY, Kim JW, Huh W, Ko JW, Kim JS, Lee SY.

Clin Ther. 2011 Oct;33(10):1371-80. doi: 10.1016/j.clinthera.2011.09.004. Epub 2011 Oct 6.

PMID:
21981797
6.

Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation.

Verhoef TI, Redekop WK, Veenstra DL, Thariani R, Beltman PA, van Schie RM, de Boer A, Maitland-van der Zee AH; EU-PACT Group..

Pharmacogenomics. 2013 Jun;14(8):869-83. doi: 10.2217/pgs.13.74.

PMID:
23746182
7.

Should we test for CYP2C9 before initiating anticoagulant therapy in patients with atrial fibrillation?

Eckman MH, Greenberg SM, Rosand J.

J Gen Intern Med. 2009 May;24(5):543-9. doi: 10.1007/s11606-009-0927-7. Epub 2009 Mar 3.

8.

A randomized trial of genotype-guided dosing of warfarin.

Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, Kesteven P, Christersson C, Wahlström B, Stafberg C, Zhang JE, Leathart JB, Kohnke H, Maitland-van der Zee AH, Williamson PR, Daly AK, Avery P, Kamali F, Wadelius M; EU-PACT Group..

N Engl J Med. 2013 Dec 12;369(24):2294-303. doi: 10.1056/NEJMoa1311386. Epub 2013 Nov 19.

9.

Universal versus genotype-guided use of direct oral anticoagulants in atrial fibrillation patients: a decision analysis.

You JH.

Pharmacogenomics. 2015;16(10):1089-100. doi: 10.2217/pgs.15.64. Epub 2015 Jul 31.

PMID:
26230572
10.

A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding.

McClain MR, Palomaki GE, Piper M, Haddow JE.

Genet Med. 2008 Feb;10(2):89-98. doi: 10.1097/GIM.0b013e31815bf924. Review.

PMID:
18281915
11.

Warfarin sensitivity genotyping: a review of the literature and summary of patient experience.

Moyer TP, O'Kane DJ, Baudhuin LM, Wiley CL, Fortini A, Fisher PK, Dupras DM, Chaudhry R, Thapa P, Zinsmeister AR, Heit JA.

Mayo Clin Proc. 2009 Dec;84(12):1079-94. doi: 10.4065/mcp.2009.0278. Review.

12.

Extremely low warfarin dose in patients with genotypes of CYP2C9*3/*3 and VKORC1-1639A/A.

Gao L, He L, Luo J, Xu B, Yang J, Zhang YX, Yang T, Li K, Tian JW, Wang HJ, Zhao YS, Lu CY, Zhang WZ, Yin T.

Chin Med J (Engl). 2011 Sep;124(17):2767-70.

PMID:
22040439
13.

Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin.

Schwartz JB, Kane L, Moore K, Wu AH.

J Am Med Dir Assoc. 2011 Nov;12(9):633-8. doi: 10.1016/j.jamda.2010.12.006. Epub 2011 Jan 26.

PMID:
21450231
14.

[Warfarin resistance and related pharmacogenetic information].

Takahashi H.

Brain Nerve. 2008 Nov;60(11):1365-71. Review. Japanese.

PMID:
19069171
15.

Prospective pilot trial of PerMIT versus standard anticoagulation service management of patients initiating oral anticoagulation.

Borgman MP, Pendleton RC, McMillin GA, Reynolds KK, Vazquez S, Freeman A, Wilson A, Valdes R Jr, Linder MW.

Thromb Haemost. 2012 Sep;108(3):561-9. doi: 10.1160/TH12-03-0159. Epub 2012 Jul 26.

16.

Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy.

Linder MW, Bon Homme M, Reynolds KK, Gage BF, Eby C, Silvestrov N, Valdes R Jr.

Clin Chem. 2009 Oct;55(10):1861-8. doi: 10.1373/clinchem.2009.125898. Epub 2009 Aug 13.

17.

Patient-specific decision-making for warfarin therapy in nonvalvular atrial fibrillation: how will screening with genetics and imaging help?

Eckman MH, Wong LK, Soo YO, Lam W, Yang SR, Greenberg SM, Rosand J.

Stroke. 2008 Dec;39(12):3308-15. doi: 10.1161/STROKEAHA.108.523159. Epub 2008 Oct 9.

18.

Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation.

Catherwood E, Fitzpatrick WD, Greenberg ML, Holzberger PT, Malenka DJ, Gerling BR, Birkmeyer JD.

Ann Intern Med. 1999 Apr 20;130(8):625-36.

PMID:
10215558
19.

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.

Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, Kahn SF, May HT, Samuelson KM, Muhlestein JB, Carlquist JF; Couma-Gen Investigators..

Circulation. 2007 Nov 27;116(22):2563-70. Epub 2007 Nov 7.

20.

Should we be applying warfarin pharmacogenetics to clinical practice? No, not now.

Rosove MH, Grody WW.

Ann Intern Med. 2009 Aug 18;151(4):270-3, W95.

PMID:
19687493

Supplemental Content

Support Center